AI Article Synopsis

  • Multimorbidity, particularly the coexistence of obesity and tobacco use disorder (TUD), is linked to varying risks for substance use disorders (SUDs) and psychiatric conditions among individuals.
  • Data from a large survey indicated that individuals with obesity or those with both obesity and TUD had lower rates of SUD diagnosis compared to those with TUD alone.
  • The study suggests that obesity might mitigate the risk of developing SUDs, providing insights that could enhance targeted intervention strategies for affected populations.

Article Abstract

Background: Multimorbidity is linked to worse health outcomes than single health conditions. However, recent studies show that obesity may reduce the risk of developing substance use disorders (SUDs), particularly in vulnerable populations. We investigated how comorbid obesity and tobacco use disorder (TUD) relate to the risk of SUDs and psychiatric conditions.

Methods: Data was used from 36,309 individuals who completed the National Epidemiological Survey on Alcohol and Related Conditions - Wave III. Individuals who met the DSM-5 criteria for TUD in the last year were defined as the TUD group. Obesity was defined as having a body mass index (BMI) greater than 30 kg/m. Using this information, individuals were grouped into categories, with people being identified as either having obesity, TUD, both obesity and TUD, or not having either obesity or TUD (comparison). Groups were compared against their comorbid diagnoses of either an additional SUD or psychiatric conditions.

Results: Controlling for demographic characteristics, we found that individuals with obesity including those individuals with TUD, had lower rates of comorbid SUD diagnosis than individuals with TUD alone. Additionally, individuals with combined TUD and obesity, and those with TUD alone, had the highest rates of comorbid psychiatric disorder diagnosis.

Conclusions: The current study aligns with previous research suggesting that obesity may reduce risk of substance use disorders, even in individuals who have other risk factors promoting harmful substance use (e.g., tobacco use). These findings may inform targeted intervention strategies for this clinically relevant subpopulation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163607PMC
http://dx.doi.org/10.1016/j.dadr.2023.100162DOI Listing

Publication Analysis

Top Keywords

obesity tud
16
substance disorders
12
tud obesity
12
obesity
10
tud
10
obesity tobacco
8
tobacco disorder
8
obesity reduce
8
reduce risk
8
individuals
8

Similar Publications

Evidence from clinical studies of leptin: current and future clinical applications in humans.

Metabolism

December 2024

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA.

Leptin has been established as the prototype adipose tissue secreted hormone and as a major regulator of several human physiology functions. Here, we are primarily reviewing the findings from studies in humans involving leptin administration. We are describing the metabolic, endocrine and immunologic effects of leptin replacement in conditions of leptin deficiency, such as short-term fasting in healthy individuals, relative energy deficiency in sports (REDS), congenital leptin deficiency (CLD), generalized (GL) and partial lipodystrophy (PL), HIV-associated lipodystrophy (HIV-L) and of leptin treatment in conditions of leptin excess (common obesity, type 2 diabetes, steatotic liver disease).

View Article and Find Full Text PDF

Tobacco use represents the leading preventable risk factor for premature deaths worldwide. A meta-analysis of 74 epidemiological studies, including 3.2 million individuals with type 2 diabetes mellitus (T2DM) from 33 countries, reported a pooled prevalence of smoking of 20.

View Article and Find Full Text PDF

Background: Recent data are inconclusive regarding the risk of arrhythmias among young cannabis users. Furthermore, many young adults use both cannabis and tobacco, which could add a residual confounding effect on outcomes. So, we studied young men who have cannabis use disorder (CUD) excluding tobacco use disorder (TUD) to understand their independent association with atrial fibrillation (AF) and related outcomes.

View Article and Find Full Text PDF

Background: Reports of reduced desire to smoke in patients treated with semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus (T2DM) and obesity, have raised interest about its potential benefit for tobacco use disorders (TUDs).

Objective: To examine the association of semaglutide with TUD-related health care measures in patients with comorbid T2DM and TUD.

Design: Emulation target trial based on a nationwide population-based database of patient electronic health records.

View Article and Find Full Text PDF
Article Synopsis
  • Recent genomic studies have found common genetic factors among alcohol, opioid, tobacco, and cannabis use disorders, though the specific genes and variants involved remain largely unknown.
  • Researchers utilized advanced genomic datasets from various human cell types to investigate genomic regions related to these disorders, identifying significant heritability enrichments in specific cell types, especially in iPSC-derived cortical neurons and pancreatic beta cells.
  • The study also uncovered important genetic connections between substance use disorders and Type 2 diabetes, suggesting that certain cell types play crucial roles in understanding the mechanisms behind these disorders.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!